ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Taking PMN Private

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Dec 01, 2021 4:35pm

93 Views

Post# 34187140

RE:RE:RE:Taking PMN Private

I will only fold my hand if Phase 1 does not pass muster. So I'm a long way off from folding. And if Nasdaq precedes the Phase 1 study all the better.

Was anything said about Nasdaq today at the special meeting that I failed to engage in?

G1945V

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project